PP
FOMX

PDT Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

PDT Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29,600
Closed -$148K – 564
2018
Q2 		$148K Sell
29,600
-5,500
-16% -$28.3K 0.01% 488
2018
Q1 		$180K Buy
35,100
+2,200
+7% +$13.2K 0.01% 530
2017
Q4 		$198K Sell
32,900
-16,400
-33% -$98.7K 0.01% 508
2017
Q3 		$274K Sell
49,300
-16,200
-25% -$83.7K 0.01% 476
2017
Q2 		$304K Buy
+65,500
New +$292K 0.01% 454
2015
Q4 		– Sell
-58,052
Closed -$426K – 1113
2015
Q3 		$426K Sell
58,052
-1,184
-2% -$12.1K 0.01% 949
2015
Q2 		$607K Buy
+59,236
New +$655K 0.02% 909

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

PDT Partners's FOMX Position: Q3 2018 in Review

PDT Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2018, closing a stake of 29,600 shares — an estimated $148K sold.

PDT Partners first reported a position in FOMX in Q2 2015 and held it in 7 quarters. The position peaked at $607K in Q2 2015. 75 funds tracked by Wall St. Rank hold FOMX as of Q3 2018.

  • PDT Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2018 after selling out during the quarter.
  • PDT Partners sold 29,600 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2018, an estimated $148K.
  • PDT Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 7 quarters.
  • PDT Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $607K in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2018.

Based on PDT Partners's 13F filing for Q3 2018, filed 14 Nov 2018.